期刊
STEM CELLS TRANSLATIONAL MEDICINE
卷 2, 期 1, 页码 61-67出版社
ALPHAMED PRESS
DOI: 10.5966/sctm.2012-0120
关键词
Diabetes; Differentiation; Pancreas; Beta cells
资金
- Institut National de la Sante et de la Recherche Medicale (INSERM)
- seventh Framework Program (BetaCellTherapy) [GA241883]
- Innovative Medicines Initiative Joint Undertaking [155005]
- Beta Cell Biology Consortium
- Juvenile Diabetes Research Foundation
- Agence Nationale de la Recherche
- Endo Cells SARL
It is well-established that insulin-producing pancreatic beta cells are central in diabetes. In type 1 diabetes, beta cells are destroyed by an autoimmune mechanism, whereas in type 2 diabetes, there is a decrease in functional beta-cell mass. In this context, studying beta cells is of major importance. Beta cells represent only 1% of total pancreatic cells and are found dispersed in the pancreatic gland. During the past decades, many tools and approaches have been developed to study rodent beta cells that efficiently pushed the field forward. However, rodent and human beta cells are not identical, and our knowledge of human beta cells has not progressed as quickly as our understanding of rodent beta cells. We believe that one of the reasons for this inefficient progress is the difficulty of accessing unlimited sources of functional human pancreatic beta cells. The main focus of this review concerns recent strategies to generate new sources of human pancreatic beta cells. STEM CELLS TRANSLATIONAL MEDICINE 2013;2:61-67
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据